Skip to main content
. 2017 Dec 1;61(6):584–589. doi: 10.1590/2359-3997000000307

Table 1. Cohort description.

Characteristic N = 211 %
Gender (F:M) 150:61 71.1:28.9
Age at diagnosis (years) 41 (21-77) -
Size (cm) 2.2 (0.3-15) -
Race
White 146 69.2
Black 10 4.7
Latin 51 24.2
Not informed 4 1.9
Size (cm) 2.2 (0.3-15) -
Total thyroidectomy 211 100
Histology
PTC 192 90.9
Invasive follicular variant of PTC 13 6.2
Hurthle variant 3 1.4
FTC 3 1.4
ETE 121 57.3
Multifocality 103 48.8
Vascular invasion 63 29.9
cN1 131 62.1
Lymph node staging
> 5 metastatic lymph nodes 99 46.9
> 3 cm metastatic lymph node 40 19
Central compartment only (N1A) 91 43.1
Lateral compartment (N1B) 102 48.3
Extra nodal extension 15 7.1
Distant metastasis 27 12.8
RAI 211 100
Initial activity (mCi) 150 (30-250) -
Total activity (mCi) 200 (100-1100) -
ATA 2015 risk
Low 21 9.9
Intermediate 110 52.1
High 80 38
Follow-up (years) 6.2 (0.8-17) -
Final status
NED with additional therapy 89 42.2
Biochemical persistent disease 74 35.1
Structural persistent disease 43 20.4
Deaths 5 2.4

PTC: papillary thyroid cancer; FTC: follicular thyroid cancer; ETE: extrathyroidal extension; NED: no evidence of disease; ATA: American Thyroid Association; RAI: radioactive iodine.